May 19, 2016 10:49am

Single patient study needs to be taken in context; overbought - SELL

 


In an online report published in the “International Journal of the Cardiovascular Academy”, Cesca Therapeutics (KOOL) published data from a single patient study that showed a significant improvement in the Left Ventricular Ejection Fraction (LVEF) using Cesca’s integrated point-of-care technology, Acute Myocardial Infarction Rapid Stem cell Therapy (AMIRST).

According to Dr. Venkatesh Ponemone, study director and executive director of TotipotentRX, a KOOL subsidiary, the patient was able to return to normal life two weeks after the AMIRST procedure, and the main findings of the study showed a significant improvement in the Left Ventricular Ejection Fraction (LVEF) from 35% at patient’s initial assessment to 60.3% at 24 months post-AMIRST intervention. 

LVEF is a key indicator of cardiac function, and reduced LVEF levels are considered risk factors for cardiovascular morbidity and mortality. 

The Bottom Line:  Hold on to your wallets as the published data comes from A SINGLE PATIENT STUDY!  To his credit, study director Dr. Ponemone said, “this degree of improvement is considered atypical for a patient having suffered an ST elevated myocardial infarction (STEMI) with an ejection fraction below 40% post reperfusion (stenting).”

KOOL closed UP +$0.02 to $2.01 on Wednesday and is SKYROCKETING +$0.61 or +30.35% to $2.62 during Thursday morning’s trading session. -- SELL